# US 2022/0009916 A1 · Acetylation writer inhibitor development and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009916 A1
- Document ID: US20220009916A1
- Status: Published application
- Kind: A1
- Application number: 17/289,662
- Filed: 2019-11-01
- Published: 2022-01-13
- Earliest claimed: 2018-11-02
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Jun Qi; Adam D. Durbin
- Web page: https://patentgrep.com/patent/US20220009916A1

## CPC

- C07D 413/14: containing three or more hetero rings
- C07D 495/04: Ortho-condensed systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 417/14: containing three or more hetero rings
- C12N 15/09: Recombinant DNA-technology
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are bifunctional compounds (degraders) that target HAT EP300 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

## Claims

### Claim 1

A bifunctional compound having a structure represented by formula I:
wherein the targeting ligand represents a moiety that binds histone acetyltransferase (HAT) EP300, the degron represents a moiety that binds an E3 ubiquitin ligase, and the linker represents a moiety that covalently connects the degron and the targeting ligand, or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 2 (depends on 1)

The bifunctional compound of claim 1, wherein the EP300 targeting ligand is A-485 or an A-485 analog, and is represented by structure TL-1 or TL-1a:
wherein A is CH2, NH or O;
B is CH2 or CO;
and R is H, halo, CN, CF3, alkyl or alkoxy.

### Claim 3 (depends on 2)

The bifunctional compound of claim 2, which is represented by structure I-1 or I-1a:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim at position 4

-5. (canceled)

### Claim 6 (depends on 1)

The bifunctional compound of claim 1, wherein the EP300 targeting ligand is represented by an one of structures TL-1b to TL-1F:
wherein
R1 a C3-C5 carbocyclic or alkcarbocyclic group or a 3-5 membered N-heterocyclic or alkN-heterocyclic group, and wherein the alkyl group is a C1-C10 alkyl group;
wherein
Q is CH2, O, N, CO, C(O)O, C(O)N, CH2N, CH2C(O), CH2C(O)O, CH2C(O)N, or CH2CH2N,
and R2 is
a CF3, a C3-C5 carbocyclic or alkcarbocyclic group or a 3-5 membered N-heterocyclic or alkN-heterocyclic group, and wherein the alkyl group is a C1-C10 alkyl group;

### Claim 7 (depends on 6)

The compound of claim 6, wherein R1 is

### Claim 8 (depends on 6)

The bifunctional compound of claim 6, which is represented by any one of structures I-1b to Ib-1F:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim at position 8

-16. (canceled)

### Claim 17 (depends on 1)

The bifunctional compound of claim 1, wherein the linker is represented by structure L10:
wherein X is CH2, NH, NMe, or O; and n is an integer from 0 to 11.

### Claim 18 (depends on 1)

The bifunctional compound of claim 1, wherein the linker is represented by any one of structures L11 to L26:

### Claim 19 (depends on 1)

The bifunctional compound of claim 1, which is represented by any one of structures I-2 to I-12:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 20 (depends on 1)

The bifunctional compound of claim 1, which is represented by a structure selected from the group consisting of:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 21 (depends on 1)

The bifunctional compound of claim 1, wherein the degron binds cereblon (CRBRN).

### Claim 22 (depends on 21)

The bifunctional compound of claim 21, wherein the degron is represented by structure D1:
wherein Y is CH2 or CO;
and Z is NH, O, or OCH2CO and the squiggle () represents the point of attachment for the linker and EP300 targeting moiety.

### Claim 23 (depends on 21)

The bifunctional compound of claim 21, wherein the degron is represented by structure D1-a:

### Claim 24 (depends on 1)

The bifunctional compound of claim 1, wherein the degron binds von Hippel Landau tumor suppressor (VHL).

### Claim 25 (depends on 24)

The bifunctional compound of claim 24, wherein the degron is represented by a structure selected from the group consisting of:
wherein Y′ is a bond, N, O or C;
wherein Z is a C5-C6 carbocyclic or a C5-C6 heterocyclic group; and

### Claim 26 (depends on 1)

The bifunctional compound of claim 1, which is represented by any one of structures 1 and 3-23:
and pharmaceutically acceptable salts and stereoisomers thereof.

### Claim 27

A bifunctional compound having a structure represented by formula II:
wherein the targeting ligand represents a moiety that binds histone acetyltransferase p300, the linker represents a moiety that covalently connects biotin and the targeting ligand, or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 28 (depends on 27)

The bifunctional compound of claim 27, which is represented by a structure selected from the group consisting of:
or a stereoisomer thereof.

### Claim 29 (depends on 27)

The bifunctional compound of claim 27, which is represented by structure 24:
or a stereoisomer thereof.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the bifunctional compound of formula (I) or pharmaceutically acceptable salt or stereoisomer of claim 1, and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, which is in the form of a tablet or capsule.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

A method of treating a disease or disorder involving dysregulated EP300 activity, comprising administering a therapeutically effective amount of the bispecific compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof of claim 1, to a subject in need thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein the disease or disorder is an EP300-dependent and a MYC-family dependent cancer.

### Claim 35 (depends on 33)

The method of claim 33, wherein the disease or disorder is high-risk neuroblastoma (NB).

### Claim 36 (depends on 33)

The method of claim 33, wherein the disease or disorder is acute myeloid leukemia (AML), multiple myeloma (MM), or diffuse large B cell lymphoma.

### Claim 37 (depends on 33)

The method of claim 33, the disease or disorder is a solid tumor selected from melanoma, rhabdomyosarcoma, colon cancer, rectum cancer, stomach cancer, breast cancer, and pancreatic cancer.

### Claim 38

(canceled)

### Claim 39 (depends on 35)

The method of claim 35, wherein the method further comprises administering the therapeutically effective amount of the bifunctional compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, to the subject, in combination with a therapeutically effective amount of an additional anti-NB agent.

### Claim 40 (depends on 33)

The method of claim 33, wherein the therapeutically effective amount of the bifunctional compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, is administered orally to a subject in the form of a tablet or capsule.

### Claim 41

(canceled)

### Claim 42 (depends on 33)

The method of claim 33, wherein the therapeutically effective amount of the bifunctional compound of formula I or a pharmaceutically acceptable salt, or stereoisomer thereof, is administered parenterally to the subject in the form of a liquid.

### Claim 43 (depends on 33)

The method of claim 33, wherein the bifunctional compound of formula (I) is administered to the subject in the form of a salt.

### Claim 44

(canceled)

### Claim 45 (depends on 27)

A method of isolating or detecting EP300 bromodomain, comprising contacting lysed cells suspected of containing EP300 with the bifunctional compound of claim 27 and streptavidin immobilized on a carrier; isolating complexes formed by molecule and protein binding through biotin-streptavidin binding; and confirming presence of EP300 in complex.

### Claim 46 (depends on 45)

The method of claim 45, wherein the carrier comprises beads.
